Skip to main content

Table 1 Binding affinity (Kd), structure, and inhibitors of the critical PPIs involving MLL1

From: Structure, function and inhibition of critical protein–protein interactions involving mixed lineage leukemia 1 and its fusion oncoproteins

PPIs Kd (μM) Structures (PDB code) Inhibitors
Menin–MLL1 0.01 or 0.082 [44, 45] 3U85 [45], 4GQ6 [46] [16, 46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68]
LEDGF–Menin–MLL1 0.47 or 1.4 [45, 69] 3U88 [45] [69, 70]
LEDGF–MLL1 14.7 [69] 2MTN [69], 2MSR [70] and 6EMQ [71] [70]
MLL1(PHD3)-H3K4me3 19 or 30 [31, 72] 3LQJ [30] None
MLL1(PHD3)-H3K4me2 158 [31] 3LQI [30] None
MLL1(PHD3-BRD)-H3K4me3 4.3 [30] 3LQJ [30] None
MLL1(PHD3-BRD)-H3K4me2 6.9 [30] 3LQI [30] None
MLL1(PHD3)-Cyp33 14.7 [72] 2KU7 [30] None
MLL1-CBP(KIX) 2.8 or 3.8 [73, 74] 2AGH [75] [76,77,78]
MLL1-RbBP5-ASH2L 126 [19] 5F6L [19] None
MLL3-RbBP5-ASH2L 0.13 [19] 5F6K [19] None
MLL1-WDR5-RbBP5 None 3P4F [79] None
MLL1-WDR5 0.12 or 1.7 [80, 81] 3EG6 [81], 3EMH [82], and 4ESG [83] [36, 81, 84,85,86,87,88,89,90,91,92,93,94,95,96,97,98,99,100,101,102,103]